Clinical Trial Update: Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy, safety, and pharmacokinetics of Gammaplex in primary immunodeficiency diseases completed with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Variable Immunodeficiency
• Hyper-igm Syndrome
• Hypogammaglobulinemia
• Immunodeficiency
• Wiskott-aldrich Syndrome
• X-linked Agammaglobulinemia

Drugs mentioned

• GAMMAPLEX (intravenous immunoglobulin (IVIG))

Snippet

Sponsor: Bio Products Laboratory | Conditions: Primary Immunodeficiency, Common Variable Hypogammaglobulinemia | Phase 3 | Status: COMPLETED | Results posted: 2010-01-28